In an interview at the 18th British Thoracic Oncology Group (BTOG) 2020 congress, Sanjay Popat, BSc, MBBS, FRCP, PhD, of The Royal Marsden NHS Foundation Trust in London, UK, provides an update on recent mesothelioma trials, including CONFIRM, BEAT-meso, and MARS2. CONFIRM is designed to compare the best supportive care with nivolumab in the relapsed setting. BEAT-meso is a trial investigating the potential enhanced benefit of immunotherapy to chemotherapy plus a VEGF inhibitor. Dr. Popat notes that MARS2 was designed to investigate the role of surgery in mesothelioma.